Teva’s generic drug portfolio continues to expand and yield returns
Teva Pharmaceuticals successfully developed and marketed several generic drugs in recent years. In March 2022, the company announced the first generic version of Revlimid, a treatment for myeloma and some forms of lymphoma, the reported annual sales of $2.3 billion in 2021. In December 2021, the company launched the first generic version of Narcan, a nasal spray used in opioid overdoses and emergencies. Earlier that month, Teva released a generic version of Epiduo Forte Gel, an acne medication with annual sales of $253.0 million in 2021. Teva’s generic portfolio consists of over 500 medicines.
Balance Sheet|New ActivityIn response to volatile demand in the wake of the first COVID-19 surge, the company undertook a comprehensive cost reduction program, aimed at shoring up labor and supply costs.
Lorem Ipsum text header Report Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Maecenas non leo lacinia, consectetur ipsum non, pretium augue. Vestibulum accumsan dignissim massa, eu scelerisque mi malesuada ut. Aliquam scelerisque facilisis nisl ac varius. Nunc luctus nunc vel eros iaculis, vitae tristique ante fringilla. Ut vitae vulputate est, vel lacinia nisi. Curabitur eget nulla vitae mi faucibus imperdiet. Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.
Cras sagittis arcu eu diam pharetra iaculis eget sit amet risus. Morbi eget turpis ut diam commodo congue id eu lacus.